US President Donald Trump’s administration is likely to impose duties on the import of medicines under the investigation under the “Section 232”. This allows you to impose duties because of national security. This was stated on Thursday by the White House business advisor Peter Navarro for CNBC. TASR reports this based on the Reuters report.
According to Navarr, it is “clear that we have a national security crisis”, since The US is dependent on foreign producers in this sector. Navarro did not provide any details of the timing of the investigation under Section 232 in the CNBC interview.
He only stated that “President Donald Trump’s executive order for strengthening the supply chains will provide price lower boundaries for domestic drug manufacturers through long -term strategic contracts to secure sufficient demand ”. At the same time, duties discourage the dumping of pharmaceutical precursors from India and China, added.
